Athena Athena

X
[{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Sirtex Medical","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"$30.0 million","newsHeadline":"Sirtex Medical closes Strategic Transaction with OncoSec Medical","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"February 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"The Australian Research and Development Tax Incentive","pharmaFlowCategory":"D","amount":"$1.7 million","upfrontCash":"Undisclosed","newsHeadline":"OncoSec Receives $850,000 from The Australian R&D Tax Incentive Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoSec Announces Publication of Positive TAVO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"OncoSec Immunotherapies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OncoSec Collaborates with Providence Cancer Institute to Conduct First-in-Human Trial of OncoSec's CORVax12","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoSec to Present Two Late-Breaking Pre-Clinical Abstracts on TAVO-PLUS at the AACR Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoSec Strengthens IP Portfolio with Three New Patents Covering TAVO\u2122 and Its Electroporation Gene Delivery System","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoSec Expands KEYNOTE-890 Trial into First-Line Metastatic Triple Negative Breast Cancer with TAVO\u2122 and KEYTRUDA\u00ae Plus Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoSec Presents Two Late-Breaking Abstracts on TAVO-PLUS at the American Association for Cancer Research (AACR) Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoSec Starts a Phase 2 Study at the Moffitt Cancer Center to Evaluate Combination of TAVO plus OPDIVO\u00ae as Neoadjuvant Therapy for Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoSec Announces Issuance of New U.S. Patent Expanding Coverage of TAVO\u2122 and Its Gene Delivery Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoSec Announces FDA Clearance of IND Application for Initiation of Phase 1 Clinical Trial of its CORVax12 Vaccine Candidate for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoSec to Present Positive Interim Data from KEYNOTE-695 Trial in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma at SITC 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoSec Strengthens IP Portfolio with Allowance of Two European Patent Applications Covering TAVO\u2122 and Its Gene Electrotransfer Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed"},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Sirtex Medical","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"OncoSec Enters into Option Agreement with Sirtex Medical to Co-Promote TAVO\u2122","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoSec Announces First Subjects Dosed in Phase 1 Trial of CORVax12","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoSec to Present Encore Interim Data from the KEYNOTE-695 Phase 2b Clinical Trial at the 10th World Congress of Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoSec Medical Hosting SITC Key Opinion Leader Webinar on Updated Data from the KEYNOTE-695 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"}]

Find Clinical Drug Pipeline Developments & Deals by Oncosec Medical

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Tavo works by optimizing cellular uptake of DNA-based IL-12 recruits and primes immune cancer-fighting cells in the tumor leading to systemic immune responses without systemic toxicity.

            Lead Product(s): Tavokinogene Telseplasmid,Pembrolizumab

            Therapeutic Area: Oncology Product Name: Tavo

            Highest Development Status: Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 02, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            KEYNOTE-695 is OncoSec's registration-directed Phase 2b trial evaluating TAVO, a DNA plasmid-based interleukin-12 (IL-12) + KEYTRUDA® (pembrolizumab) in patients with rigorously confirmed anti-PD-1 checkpoint resistant metastatic melanoma.

            Lead Product(s): Tavokinogene Telseplasmid,Pembrolizumab

            Therapeutic Area: Oncology Product Name: TAVO

            Highest Development Status: Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 15, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The CORVax12 vaccine approach combines the co-administration of OncoSec’s TAVO with a DNA-encodable version of the SARS-CoV-2 spike glycoprotein to boost the immunogenicity of the component developed by NIAID Vaccine Research Center scientists.

            Lead Product(s): SARS-CoV-2 spike protein plasmid DNA vaccine,Tavokinogene Telseplasmid

            Therapeutic Area: Infections and Infectious Diseases Product Name: CORVax12

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: National Institutes of Health

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 27, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Through this agreement, Sirtex gains an option to non-exclusively co-promote the Company's lead product candidate, TAVO™ (tavokinogene telseplasmid) in anti-PD-1 checkpoint refractory metastatic melanoma in the U.S.

            Lead Product(s): Tavokinogene Telseplasmid,Pembrolizumab

            Therapeutic Area: Oncology Product Name: Tavo

            Highest Development Status: Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Sirtex Medical

            Deal Size: $30.0 million Upfront Cash: Undisclosed

            Deal Type: Agreement January 19, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The applications are directed to the use of OncoSec's interleukin-12 (IL-12)-based immunotherapy platform, including its lead product candidate TAVO™ delivered with the Company's proprietary intratumoral gene electrotransfer system for the treatment of cancer.

            Lead Product(s): Tavokinogene Telseplasmid,Undisclosed

            Therapeutic Area: Oncology Product Name: Tavo

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 10, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            OncoSec will present new positive interim data from its KEYNOTE-695 registration-enabled Phase 2b clinical trial investigating TAVO™ in combination with KEYTRUDA® in patients with anti-PD-1 checkpoint refractory metastatic melanoma at 35th SITC Annual Meeting.

            Lead Product(s): Tavokinogene Telseplasmid,Pembrolizumab

            Therapeutic Area: Oncology Product Name: Tavo

            Highest Development Status: Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 03, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            CORVax12 is the first next-generation DNA vaccine candidate to deliver spike (S) protein from SARS-CoV-2 plus immune-stimulating interleukin-12 (IL-12) to elicit T-cell activation and drive robust humoral immunity.

            Lead Product(s): SARS-CoV-2 spike protein plasmid DNA vaccine,Tavokinogene Telseplasmid

            Therapeutic Area: Infections and Infectious Diseases Product Name: CORVax12

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 29, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Patent covers the use of intratumoral electroporation of DNA encoding interleukins to treat cancer and is significant because it is not specific to which type of immune-stimulatory interleukin can be used to treat a patient, nor is it limited to a particular type of cancer.

            Lead Product(s): Tavokinogene Telseplasmid,Pembrolizumab

            Therapeutic Area: Oncology Product Name: Tavo

            Highest Development Status: Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 06, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Anti-PD-1 immune checkpoint therapies, such as OPDIVO®, are an established first-line treatment for advanced melanoma, and encouraging clinical data suggest that they have clinically meaningful activity in the neoadjuvant setting as well.

            Lead Product(s): Tavokinogene Telseplasmid,Nivolumab

            Therapeutic Area: Oncology Product Name: Tavo

            Highest Development Status: Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 27, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            OncoSec Medical Incorporated presented new data further demonstrating the power of OncoSec's next-generation IL-12 plasmid (TAVOPLUS) therapeutic when combined with a T cell stimulator (TAVOPLUS-CD3) or an enhanced chemokine gradient (TAVOPLUS-CXCL9).

            Lead Product(s): Tavokinogene Telseplasmid,Undisclosed

            Therapeutic Area: Oncology Product Name: Tavo plus

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 22, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY